Results from a Phase III study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida today show that patients with advanced non-small cell lung cancer (NSCLC) who received erlotinib (Tarceva®) as first-line maintenance treatment benefited from a significant (29%) improvement in the time they lived without the disease advancing, compared with those who received placebo1. Patients in the global multicentre SATURN trial, which included patients from the UK, received maintenance treatment with erlotinib if their cancer had not progressed on initial chemotherapy. The data showed a significant improvement in the length of time patients lived without their disease getting worse, and without the need for further chemotherapy. 1 The improvement was seen in both of the main types of NSCLC (squamous cell as well as non-squamous cell) and these results form the basis of a submission for regulatory approval of erlotinib to be used in the first-line maintenance setting. 1 Erlotinib is not currently licensed for first line maintenance treatment in NSCLC lung cancer in the UK.
generic viagra online
Nanobiotix, an emerging nanomedicine company, announced exciting preclinical results using its patented nanoXray therapeutics platform to fight tumors. The preclinical study, performed at Institut Gustave Roussy, one of Europe"s leading cancer treatment centers, showed that an intratumoral injection of NBTXR3 nanoparticles and activated via standard radiation therapy led to complete tumor regression in mice at 60 days, compared to zero tumor regression in mice treated with xray only or NBTXR3 only. The study was led by principal investigator, Jean Bourhis, M.D., Ph.D. a prominent radiation oncologist and researcher at Institut Gustave Roussy.
Health Canada and the Canadian Food Inspection Agency (CFIA) are reminding Canadians that fresh fiddleheads should be properly cooked before being consumed.
Two pharmacists, and one non-pharmacist, have been recognised by the Council of the Royal Pharmaceutical Society of Great Britain in its 2009 awards for their outstanding contributions to the pharmacy profession. Ann Lewis, a Fellow of the Society and former Secretary and Registrar, was awarded the Charter Gold Medal by Council at its Annual General Meeting on Wednesday 20 May. Fellow pharmacist Digby Emson, also a Fellow of the Society, was the recipient of the Charter Silver
Medal for his work in various areas of community pharmacy. He is Chairman of the Company Chemists" Association (CCA). Digby Emson"s daughter, Lorne Emson, accepted the Charter Silver Medal on his behalf. Member of Parliament, Dr Howard Stoate was presented with the Synergy Award for his exceptional achievement in furthering the profession through his representation on parliamentary pharmacy and health-related committees.
Cancer Centers of North Carolina, an affiliate of US Oncology, Inc., continues to offer cutting-edge treatment options to its patients through the addition of High Dose Rate (HDR) brachytherapy. This latest advance in brachytherapy allows physicians to deliver precise radiation treatment to a patient"s cancerous tumor and is rapidly becoming the treatment of choice for certain types of cancer. With HDR brachytherapy, radiation is delivered directly to the cancer target
through the use of catheters, needles or applicators inserted into a body cavity or directly into the tumor. A computer-controlled delivery system is used to optimize the dose distribution to the target. As a result of this precise delivery, the surrounding healthy tissue and critical organs are preferentially spared from high doses of radiation and side effects may be reduced.
Novavax, Inc. (Nasdaq: NVAX) announced it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers for Disease Control. The Company was able to reach this manufacturing goal by employing proprietary,
novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world"s influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies and stands ready to assist with additional public health needs in the US as well as foreign countries.
As the U.S. prepares for a resurgence of H1N1 influenza this fall, much can be learned from looking at a previous pandemic that had similar patterns. In an article published today in Biosecurity and Bioterrorism, researchers at the Center for Biosecurity of the University of Pittsburgh Medical Center (UPMC) examined historical documents, published material, and newspaper coverage related to the 1957-58 influenza pandemic to compare the progress and severity of that outbreak
with the current one. The simple, practical actions taken in 1957 allowed the country to continue functioning with minimal disruption. Lead author Dr. D. A. Henderson had major responsibility for establishing the CDC influenza surveillance program during the early stages of the 1957 flu; data and analysis of events presented are based on his direct experiences as well as copies of surveillance reports that were published in 1957-58.
Two pharmacists, and one non-pharmacist, have been recognised by the Council of the Royal Pharmaceutical Society of Great Britain in its 2009 awards for their outstanding contributions to the pharmacy profession. Ann Lewis, a Fellow of the Society and former Secretary and Registrar, was awarded the Charter Gold Medal by Council at its Annual General Meeting on Wednesday 20 May. Fellow pharmacist Digby Emson, also a Fellow of the Society, was the recipient of the Charter Silver
Medal for his work in various areas of community pharmacy. He is Chairman of the Company Chemists" Association (CCA). Digby Emson"s daughter, Lorne Emson, accepted the Charter Silver Medal on his behalf. Member of Parliament, Dr Howard Stoate was presented with the Synergy Award for his exceptional achievement in furthering the profession through his representation on parliamentary pharmacy and health-related committees. 
Cancer Centers of North Carolina, an affiliate of US Oncology, Inc., continues to offer cutting-edge treatment options to its patients through the addition of High Dose Rate (HDR) brachytherapy. This latest advance in brachytherapy allows physicians to deliver precise radiation treatment to a patient"s cancerous tumor and is rapidly becoming the treatment of choice for certain types of cancer. With HDR brachytherapy, radiation is delivered directly to the cancer target
through the use of catheters, needles or applicators inserted into a body cavity or directly into the tumor. A computer-controlled delivery system is used to optimize the dose distribution to the target. As a result of this precise delivery, the surrounding healthy tissue and critical organs are preferentially spared from high doses of radiation and side effects may be reduced. 
Novavax, Inc. (Nasdaq: NVAX) announced it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers for Disease Control. The Company was able to reach this manufacturing goal by employing proprietary,
novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world"s influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies and stands ready to assist with additional public health needs in the US as well as foreign countries. 
As the U.S. prepares for a resurgence of H1N1 influenza this fall, much can be learned from looking at a previous pandemic that had similar patterns. In an article published today in Biosecurity and Bioterrorism, researchers at the Center for Biosecurity of the University of Pittsburgh Medical Center (UPMC) examined historical documents, published material, and newspaper coverage related to the 1957-58 influenza pandemic to compare the progress and severity of that outbreak
with the current one. The simple, practical actions taken in 1957 allowed the country to continue functioning with minimal disruption. Lead author Dr. D. A. Henderson had major responsibility for establishing the CDC influenza surveillance program during the early stages of the 1957 flu; data and analysis of events presented are based on his direct experiences as well as copies of surveillance reports that were published in 1957-58.